TREMELIMUMAB-ACTL | B761289 | ASTRAZENECA AB
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Oct. 21, 2034 | Active | Computed |
| 7-Year Orphan | Oct. 21, 2029 | Active | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12209099(composition) · relevance 75/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 162 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Bristol-Myers Squibb Co. et al v. AstraZeneca Pharmaceuticals LP et al 2 patentstremelimumab-actl (anti-CTLA-4 antibody); ipilimumab (anti-CTLA-4 antibody); nivolumab (anti-PD-1 antibody); durvalumab (anti-PD-L1 antibody) | D. Del. | 2023-01-23 | Terminated 2023-07-31 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.